56 results on '"Jorge Polonia"'
Search Results
2. Empowerment-based nutrition interventions on blood pressure: a randomized comparative effectiveness trial
- Author
-
André Moreira-Rosário, Shámila Ismael, Inês Barreiros-Mota, Juliana Morais, Catarina Rodrigues, Inês Castela, Inês Curvelo Mendes, Maria Inês Soares, Luís Soares da Costa, Catarina Batista Oliveira, Tiago Henriques, Patrícia Pinto, Débora Pita, Catarina Marques de Oliveira, Janaína Maciel, Thaina Serafim, João Araújo, Júlio César Rocha, Diogo Pestana, Marta P. Silvestre, Cláudia Marques, Ana Faria, Jorge Polonia, and Conceição Calhau
- Subjects
cardiovascular diseases ,hypertension ,blood pressure ,mediterranean diet ,sodium/potassium ratio ,Public aspects of medicine ,RA1-1270 - Abstract
IntroductionEmpowerment lifestyle programs are needed to reduce the risk of hypertension. Our study compared the effectiveness of two empowerment-based approaches toward blood pressure (BP) reduction: salt reduction-specific program vs. healthy lifestyle general program.MethodsThree hundred and eleven adults (median age of 44 years, IQR 34–54 years) were randomly assigned to a salt reduction (n = 147) or a healthy lifestyle program (n = 164). The outcome measures were urinary sodium (Na+) and potassium (K+) excretion, systolic (SBP) and diastolic (DBP) blood pressure, weight, and waist circumference.ResultsThere were no significant differences in primary and secondary outcomes between the two program groups. When comparing each program to baseline, the program focused on salt reduction was effective in lowering BP following a 12-week intervention with a mean change of −2.5 mm Hg in SBP (95% CI, −4.1 to −0.8) and − 2.7 mm Hg in DBP (95% CI, −3.8 to −1.5) in the intention-to-treat (ITT) analysis. In the complete-case (CC) analysis, the mean change was −2.1 mm Hg in SBP (95% CI, −3.7 to −0.5) and − 2.3 mm Hg in DBP (95% CI, −3.4 to −1.1). This effect increases in subjects with high-normal BP or hypertension [SBP − 7.9 mm Hg (95% CI, −12.5 to −3.3); DBP − 7.3 mm Hg (95% CI, −10.2 to −4.4)]. The healthy lifestyle group also exhibited BP improvements after 12 weeks; however, the changes were less pronounced compared to the salt reduction group and were observed only for DBP [mean change of −1.5 mm Hg (95% CI, −2.6 to −0.4) in ITT analysis and − 1.4 mm Hg (95% CI, −2.4 to −0.3) in CC analysis, relative to baseline]. Overall, improvements in Na+/K+ ratio, weight, and Mediterranean diet adherence resulted in clinically significant SBP decreases. Importantly, BP reduction is attributed to improved dietary quality, rather than being solely linked to changes in the Na+/K+ ratio.ConclusionSalt-focused programs are effective public health tools mainly in managing individuals at high risk of hypertension. Nevertheless, in general, empowerment-based approaches are important strategies for lowering BP, by promoting health literacy that culminates in adherence to the Mediterranean diet and weight reduction.
- Published
- 2023
- Full Text
- View/download PDF
3. Unattended versus two attended, ambulatory and central blood pressure measurements in hypertensive patients with and without diabetes
- Author
-
Jorge Polonia, Cristina Baptista, Jose Silva, and Loide Barbosa
- Subjects
unattended bp ,attended bp ,24-h ,daytime bp and central bp measurements ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Objective: To compare unattended blood pressure (BP) with two attended BP, with 24-h ambulatory (ABPM) and central BP measurements in hypertensive patients with (DMs) and without diabetes (HTs). Methods: In the same hypertension clinic we evaluate 129 consecutive HTs (56% female, 59 + 16 yrs) and 91 DMs (62% female, 64 + 9 yrs) who were referred for 24-h ABPM. During 48 hours they underwent a first attended BP (5 minutes resting, 3 recordings 2 minutes apart), (AT1), an unattended BP (UnAT), 3 measurements 2 minutes apart with a pre-programmed oscillometric Omron M10- IT, a second attended BP (AT2) similar to AT1, a 24-h ABPM and an evaluation of central BP (C) from the aortic wave form (SpygmoCor). Results: BP (mm Hg) and differences (Δ) from UnAT = 135/82 ± 17/10 were 1AT = +13.8/3.9 ± 10.3/5.6, AT2 = +7.3/2.9 ± 7.4/4.9, 24-h = −1.3/−1.7 ± 7.5/7.5 and C = −2.4/1.2 ± 10.3/9.1, all p
- Published
- 2019
- Full Text
- View/download PDF
4. Aerobic exercise improves central blood pressure and blood pressure variability among patients with resistant hypertension: results of the EnRicH trial
- Author
-
Susana Lopes, José Mesquita-Bastos, Catarina Garcia, Cátia Leitão, Verónica Ribau, Manuel Teixeira, Susana Bertoquini, Ilda P. Ribeiro, Joana Barbosa de Melo, José Oliveira, Daniela Figueiredo, Guilherme V. Guimarães, Linda S. Pescatello, Jorge Polonia, Alberto J. Alves, and Fernando Ribeiro
- Subjects
Physiology ,Internal Medicine ,Cardiology and Cardiovascular Medicine - Published
- 2023
- Full Text
- View/download PDF
5. Guidelines-based therapeutic strategies for controlling hypertension in non-controlled hypertensive patients followed by family physicians in primary health care in Portugal: the GPHT-PT study
- Author
-
Jorge Polónia and Raul Marques Pereira
- Subjects
Hypertension ,primary care ,therapeutics ,multicenter study ,interventional study ,cardiovascular risk ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Purpose In a prospective open study, with intervention, conducted in Primary Health Care Units by General Practitioners (GPs) in Portugal, the effectiveness of a single pill of candesartan/amlodipine (ARB/amlodipine), as the only anti-hypertension (anti-HTN) medication, in adult patients with uncontrolled HTN (BP > 140/or > 90 mm Hg), either previously being treated with anti-HTN monotherapies (Group I), or combinations with hydrochlorothiazide (HCTZ) (Group II), or not receiving medication at all (Group III), was evaluated across 12-weeks after implementation of the new therapeutic measure.Materials and methods A total of 118 GPs recruited patients with uncontrolled HTN who met inclusion/exclusion criteria. Participants were assigned, according to severity, one of 3 (morning) fixed combination candesartan/amlodipine dosage (8/5 or 16/5 or 16/10 mg/day) and longitudinally evaluated in 3 visits (v0, v6 and v12 weeks). Office blood pressure was measured in each visit, and control of HTN was defined per guidelines (BP< 140/90 mmHg).Results Of the 1234 patients approached, 752 (age 61 ± 10 years, 52% women) participated in the study and were assigned to groups according to previous treatment conditions. The 3 groups exhibited a statistically significant increased control of blood pressure after receiving the fixed combination candesartan/amlodipine dosage. The overall proportion of controlled HTN participants increased from 0,8% at v0 to 82% at v12. The mean arterial blood pressure values decreased from SBP= 159.0 (± 13.0) and DBP= 91.1 (± 9.6) at baseline to SBP= 132,1 (± 11.3) and DBP= 77,5 (± 8.8) at 12 weeks (p
- Published
- 2024
- Full Text
- View/download PDF
6. Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney
- Author
-
Jean-Michel Halimi, Pantelis Sarafidis, Michel Azizi, Grzegorz Bilo, Thilo Burkard, Michael Bursztyn, Miguel Camafort, Neil Chapman, Santina Cottone, Tine de Backer, Jaap Deinum, Philippe Delmotte, Maria Dorobantu, Michalis Doumas, Rainer Dusing, Béatrice Duly-Bouhanick, Jean-Pierre Fauvel, Pierre Fesler, Zbigniew Gaciong, Eugenia Gkaliagkousi, Daniel Gordin, Guido Grassi, Charalampos Grassos, Dominique Guerrot, Justine Huart, Raffaele Izzo, Fernando Jaén Águila, Zoltán Járai, Thomas Kahan, Ilkka Kantola, Eva Kociánová, FlorianP. Limbourg, Marilucy Lopez-Sublet, Francesca Mallamaci, Athanasios Manolis, Maria Marketou, Gert Mayer, Alberto Mazza, IainM. MacIntyre, Jean-Jacques Mourad, Maria Lorenza Muiesan, Edgar Nasr, Peter Nilsson, Anna Oliveras, Olivier Ormezzano, Vitor Paixão-Dias, Ioannis Papadakis, Dimitris Papadopoulos, Sabine Perl, Jorge Polónia, Roberto Pontremoli, Giacomo Pucci, Nicolás Roberto Robles, Sébastien Rubin, Luis Miguel Ruilope, Lars Christian Rump, Sahrai Saeed, Elias Sanidas, Riccardo Sarzani, Roland Schmieder, François Silhol, Sekib Sokolovic, Marit Solbu, Miroslav Soucek, George Stergiou, Isabella Sudano, Ramzi Tabbalat, Istemihan Tengiz, Helen Triantafyllidi, Konstontinos Tsioufis, Jan Václavík, Markus van der Giet, Patricia Van der Niepen, Franco Veglio, RetoM. Venzin, Margus Viigimaa, Thomas Weber, Jiri Widimsky, Gregoire Wuerzner, Parounak Zelveian, Pantelis Zebekakis, Stephan Lueders, Alexandre Persu, Reinhold Kreutz, and Liffert Vogt
- Subjects
Chronic kidney disease ,hypertension ,management ,RAS blockers ,hyperkalaemia ,SGLT2 inhibitors ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Objective Real-life management of patients with hypertension and chronic kidney disease (CKD) among European Society of Hypertension Excellence Centres (ESH-ECs) is unclear : we aimed to investigate it. Methods A survey was conducted in 2023. The questionnaire contained 64 questions asking ESH-ECs representatives to estimate how patients with CKD are managed. Results Overall, 88 ESH-ECS representatives from 27 countries participated. According to the responders, renin-angiotensin system (RAS) blockers, calcium-channel blockers and thiazides were often added when these medications were lacking in CKD patients, but physicians were more prone to initiate RAS blockers (90% [interquartile range: 70–95%]) than MRA (20% [10–30%]), SGLT2i (30% [20–50%]) or (GLP1-RA (10% [5–15%]). Despite treatment optimisation, 30% of responders indicated that hypertension remained uncontrolled (30% (15–40%) vs 18% [10%–25%]) in CKD and CKD patients, respectively). Hyperkalemia was the most frequent barrier to initiate RAS blockers, and dosage reduction was considered in 45% of responders when kalaemia was 5.5–5.9 mmol/L. Conclusions RAS blockers are initiated in most ESH-ECS in CKD patients, but MRA and SGLT2i initiations are less frequent. Hyperkalemia was the main barrier for initiation or adequate dosing of RAS blockade, and RAS blockers’ dosage reduction was the usual management.
- Published
- 2024
- Full Text
- View/download PDF
7. Letter to the editor
- Author
-
Jorge Polónia and Raul Marques Pereira
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2024
- Full Text
- View/download PDF
8. The blood pressure response to acute exercise predicts the ambulatory blood pressure response to exercise training in patients with resistant hypertension: results from the EnRicH trial
- Author
-
Susana Lopes, José Mesquita-Bastos, Catarina Garcia, Daniela Figueiredo, José Oliveira, Guilherme V. Guimarães, Linda S. Pescatello, Jorge Polonia, Alberto J. Alves, and Fernando Ribeiro
- Subjects
Physiology ,Systole ,Hypertension ,Internal Medicine ,Humans ,Blood Pressure ,Blood Pressure Monitoring, Ambulatory ,Cardiology and Cardiovascular Medicine ,Exercise - Abstract
Reports suggest that the blood pressure (BP) response to an acute bout of exercise is associated with the BP response to aerobic training in participants with elevated BP. These associations have not been tested among patients with resistant hypertension. This study aimed to determine whether the BP response to acute exercise predicts the 24-h ambulatory BP response to a 12-week exercise training program in patients with resistant hypertension (n = 26, aged 59.3 ± 8.2 years, 24-h ambulatory BP 127.4 ± 12.2/75.6 ± 7.8 mm Hg) who completed the exercise arm of the EnRicH trial. Ambulatory BP measurements were obtained before and after the exercise program to assess the chronic BP response. To assess acute BP changes, resting BP was measured before and 10 min after three exercise sessions in the third week of training and averaged. The resting systolic (9.4 ± 6.7, p 0.001) and diastolic BP (1.9 ± 3.2, p = 0.005) were reduced after acute exercise. The 24-h systolic (6.2 ± 12.2, p = 0.015) and diastolic BP (4.4 ± 6.1, p = 0.001) were decreased after exercise training. The reductions in systolic BP after acute exercise were associated with the reductions in 24-h systolic BP after exercise training (ß = 0.538, adjusted r
- Published
- 2022
9. S-36-2: SOCIAL FRAMEWORK TO PROMOTE SALT REDUCTION AND HEALTHY DIETS WITHIN HYPERTENSION AND STROKE PREVENTION
- Author
-
Jorge Polonia
- Subjects
Physiology ,Internal Medicine ,Cardiology and Cardiovascular Medicine - Published
- 2023
- Full Text
- View/download PDF
10. Association of periodontitis with cerebral small vessel disease in hypertensive patients – A pilot study
- Author
-
Tiago Pinto-Ribeiro, António Felino, Ricardo Faria-Almeida, Ana Monteiro, and Jorge Polónia
- Subjects
cerebral small vessel disease ,inflammation ,periodontal disease ,white matter ,Dentistry ,RK1-715 - Abstract
Objectives: Cerebral small vessel disease is a chronic, progressive disorder of arterioles, capillaries, and small veins supplying the brain’s white matter and deep structures of gray matter. The latest evidence seems to suggest that chronic oral infections such as periodontitis contribute to cerebral small vessel disease progression. This study evaluated the relationship between periodontal disease and brain white matter hyperintensities. Methods: Forty-three hypertensive patients, aged between 38-82, without previous cardiovascular events, of which 42% were female and 50% diabetic, were evaluated. An association between mean probing depth, mean attachment level, bleeding on probing, total periodontal inflamed surface area, and white matter hyperintensities diagnosed by magnetic resonance was studied. A significance level (α) of 0.05 was considered, and Pearson’s chi-square and Mann–Whitney tests were applied. Results: Data analysis revealed an inverse correlation between mean probing depth, bleeding on probing, total periodontal inflamed surface area, and white matter hyperintensities. A positive correlation was found between mean attachment level and white matter hyperintensities. Conclusions: In our study and within our sample, lower values of mean probing depth, bleeding on probing, and total periodontal inflamed surface area were associated with more white matter hyperintensities. Contrarily, mean attachment level was positively associated with white matter hyperintensities.
- Published
- 2024
- Full Text
- View/download PDF
11. Reply
- Author
-
Jorge, Polonia, Mariana, Lobo, Luis, Martins, Fernando, Pinto, and Jose, Nazare
- Subjects
Physiology ,Internal Medicine ,Cardiology and Cardiovascular Medicine - Published
- 2017
- Full Text
- View/download PDF
12. Causality assessment of adverse drug reaction reports using an expert-defined Bayesian network
- Author
-
Pedro Pereira Rodrigues, Daniela Santos, Jorge Polonia, Ana-Marta Silva, Inês Régio Vaz, and Inês Ribeiro-Vaz
- Subjects
Activities of daily living ,Time Factors ,Databases, Factual ,Drug-Related Side Effects and Adverse Reactions ,Medicine (miscellaneous) ,030226 pharmacology & pharmacy ,Decision Support Techniques ,03 medical and health sciences ,Pharmacovigilance ,0302 clinical medicine ,Artificial Intelligence ,medicine ,Adverse Drug Reaction Reporting Systems ,Humans ,030212 general & internal medicine ,Prospective cohort study ,Adverse effect ,business.industry ,Bayesian network ,Retrospective cohort study ,Bayes Theorem ,medicine.disease ,Causality ,Medical emergency ,business ,Adverse drug reaction ,Algorithms - Abstract
In pharmacovigilance, reported cases are considered suspected adverse drug reactions (ADR). Health authorities have thus adopted structured causality assessment methods, allowing the evaluation of the likelihood that a drug was the causal agent of an adverse reaction. The aim of this work was to develop and validate a new causality assessment support system used in a regional pharmacovigilance centre. A Bayesian network was developed, for which the structure was defined by experts while the parameters were learnt from 593 completely filled ADR reports evaluated by the Portuguese Northern Pharmacovigilance Centre medical expert between 2000 and 2012. Precision, recall and time to causality assessment (TTA) was evaluated, according to the WHO causality assessment guidelines, in a retrospective cohort of 466 reports (April-September 2014) and a prospective cohort of 1041 reports (January-December 2015). Additionally, a simplified assessment matrix was derived from the model, enabling its preliminary direct use by notifiers. Results show that the network was able to easily identify the higher levels of causality (recall above 80%), although struggling to assess reports with a lower level of causality. Nonetheless, the median (Q1:Q3) TTA was 4 (2:8) days using the network and 8 (5:14) days using global introspection, meaning the network allowed a faster time to assessment, which has a procedural deadline of 30 days, improving daily activities in the centre. The matrix expressed similar validity, allowing an immediate feedback to the notifiers, which may result in better future engagement of patients and health professionals in the pharmacovigilance system.
- Published
- 2017
13. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
- Author
-
Giuseppe, Mancia, Robert, Fagard, Krzysztof, Narkiewicz, Josep, Redon, Alberto, Zanchetti, Michael, Böhm, Thierry, Christiaens, Renata, Cifkova, Guy, De Backer, Anna, Dominiczak, Maurizio, Galderisi, Diederick E, Grobbee, Tiny, Jaarsma, Paulus, Kirchhof, Sverre E, Kjeldsen, Stéphane, Laurent, Athanasios J, Manolis, Peter M, Nilsson, Luis Miguel, Ruilope, Roland E, Schmieder, Per Anton, Sirnes, Peter, Sleight, Margus, Viigimaa, Bernard, Waeber, Faiez, Zannad, Michel, Burnier, Ettore, Ambrosioni, Mark, Caufield, Antonio, Coca, Michael Hecht, Olsen, Costas, Tsioufis, Philippe, van de Borne, Jose Luis, Zamorano, Stephan, Achenbach, Helmut, Baumgartner, Jeroen J, Bax, Héctor, Bueno, Veronica, Dean, Christi, Deaton, Cetin, Erol, Roberto, Ferrari, David, Hasdai, Arno W, Hoes, Juhani, Knuuti, Philippe, Kolh, Patrizio, Lancellotti, Ales, Linhart, Petros, Nihoyannopoulos, Massimo F, Piepoli, Piotr, Ponikowski, Juan Luis, Tamargo, Michal, Tendera, Adam, Torbicki, William, Wijns, Stephan, Windecker, Denis L, Clement, Thierry C, Gillebert, Enrico Agabiti, Rosei, Stefan D, Anker, Johann, Bauersachs, Jana Brguljan, Hitij, Mark, Caulfield, Marc, De Buyzere, Sabina, De Geest, Geneviève Anne, Derumeaux, Serap, Erdine, Csaba, Farsang, Christian, Funck-Brentano, Vjekoslav, Gerc, Giuseppe, Germano, Stephan, Gielen, Herman, Haller, Jens, Jordan, Thomas, Kahan, Michel, Komajda, Dragan, Lovic, Heiko, Mahrholdt, Jan, Ostergren, Gianfranco, Parati, Joep, Perk, Jorge, Polonia, Bogdan A, Popescu, Zeljko, Reiner, Lars, Rydén, Yuriy, Sirenko, Alice, Stanton, Harry, Struijker-Boudier, Charalambos, Vlachopoulos, Massimo, Volpe, David A, Wood, Mancia, G, Fagard, R, Narkiewicz, K, Redon, J, Zanchetti, A, Böhm, M, Christiaens, T, Cifkova, R, De Backer, G, Dominiczak, A, Galderisi, M, Grobbee, D, Jaarsma, T, Kirchhof, P, Kjeldsen, S, Laurent, S, Manolis, A, Nilsson, P, Ruilope, L, Schmieder, R, Sirnes, P, Sleight, P, Viigimaa, M, Waeber, B, Zannad, F, Burnier, M, Ambrosioni, E, Caufield, M, Coca, A, Olsen, M, Tsioufis, C, Van De Borne, P, Zamorano, J, Achenbach, S, Baumgartner, H, Bax, J, Bueno, H, Dean, V, Deaton, C, Erol, C, Ferrari, R, Hasdai, D, Hoes, A, Knuuti, J, Kolh, P, Lancellotti, P, Linhart, A, Nihoyannopoulos, P, Piepoli, M, Ponikowski, P, Tamargo, J, Tendera, M, Torbicki, A, Wijns, W, Windecker, S, Clement, D, Gillebert, T, Rosei, E, Anker, S, Bauersachs, J, Hitij, J, Caulfield, M, De Buyzere, M, De Geest, S, Derumeaux, G, Erdine, S, Farsang, C, Funck Brentano, C, Gerc, V, Germano, G, Gielen, S, Haller, H, Jordan, J, Kahan, T, Komajda, M, Lovic, D, Mahrholdt, H, Ostergren, J, Parati, G, Perk, J, Polonia, J, Popescu, B, Reiner, Ž, Rydén, L, Sirenko, Y, Stanton, A, Struijker Boudier, H, Vlachopoulos, C, Volpe, M, Wood, D, Mancia, Giuseppe, Fagard, Robert, Narkiewicz, Krzysztof, Redon, Josep, Zanchetti, Alberto, Böhm, Michael, Christiaens, Thierry, Cifkova, Renata, De Backer, Guy, Dominiczak, Anna, Galderisi, Maurizio, Grobbee, Diederick E., Jaarsma, Tiny, Kirchhof, Paulu, Kjeldsen, Sverre E., Laurent, Stéphane, Manolis, Athanasios J., Nilsson, Peter M., Ruilope, Luis Miguel, Schmieder, Roland E., Sirnes, Per Anton, Sleight, Peter, Viigimaa, Margu, Waeber, Bernard, Zannad, Faiez, Burnier, Michel, Ambrosioni, Ettore, Caufield, Mark, Coca, Antonio, Olsen, Michael Hecht, Tsioufis, Costa, Van De Borne, Philippe, Zamorano, Jose Lui, Achenbach, Stephan, Baumgartner, Helmut, Bax, Jeroen J., Bueno, Héctor, Dean, Veronica, Deaton, Christi, Erol, Cetin, Ferrari, Roberto, Hasdai, David, Hoes, Arno W., Knuuti, Juhani, Kolh, Philippe, Lancellotti, Patrizio, Linhart, Ale, Nihoyannopoulos, Petro, Piepoli, Massimo F., Ponikowski, Piotr, Tamargo, Juan Lui, Tendera, Michal, Torbicki, Adam, Wijns, William, Windecker, Stephan, Clement, Denis L., Gillebert, Thierry C., Rosei, Enrico Agabiti, Anker, Stefan D., Bauersachs, Johann, Hitij, Jana Brguljan, Caulfield, Mark, De Buyzere, Marc, De Geest, Sabina, Derumeaux, Geneviève Anne, Erdine, Serap, Farsang, Csaba, Funck Brentano, Christian, Gerc, Vjekoslav, Germano, Giuseppe, Gielen, Stephan, Haller, Herman, Jordan, Jen, Kahan, Thoma, Komajda, Michel, Lovic, Dragan, Mahrholdt, Heiko, Ostergren, Jan, Parati, Gianfranco, Perk, Joep, Polonia, Jorge, Popescu, Bogdan A., Reiner, Željko, Rydén, Lar, Sirenko, Yuriy, Stanton, Alice, Struijker Boudier, Harry, Vlachopoulos, Charalambo, Volpe, Massimo, and Wood, David A.
- Subjects
Male ,Systolic hypertension ,Medical Informatic ,Blood Pressure ,Guideline ,Retinal Disease ,chemistry.chemical_compound ,Electrocardiography ,Pregnancy ,Risk Factors ,Antihypertensive treatment ,Cardiovascular Disease ,Diabetes Complication ,Drug Interactions ,Metabolic Syndrome ,Brain Diseases ,Sleep Apnea, Obstructive ,Follow-up ,Metabolic Syndrome X ,Brain Disease ,Organ damage ,Blood Pressure Monitoring, Ambulatory ,Middle Aged ,Device therapy ,Antihypertensive Agent ,Heart Disease ,Drug Interaction ,Cardiovascular Diseases ,Echocardiography ,Cerebrovascular Disorder ,Hypertension ,Cardiology ,Drug Therapy, Combination ,Female ,Cardiology and Cardiovascular Medicine ,Human ,medicine.drug ,Adult ,medicine.medical_specialty ,Ambulatory blood pressure ,Heart Diseases ,Hormone Replacement Therapy ,610 Medicine & health ,Risk Assessment ,Perioperative Care ,Diabetes Complications ,Young Adult ,Retinal Diseases ,Internal medicine ,Weight Loss ,medicine ,Humans ,Blood pressure measurement ,Renal Insufficiency, Chronic ,Exercise ,Physical Examination ,Perindopril/indapamide ,Antihypertensive Agents ,Aged ,Patient Care Team ,business.industry ,Platelet Aggregation Inhibitor ,Risk Factor ,Cardiovascular complication ,Hypertension, Pregnancy-Induced ,Aliskiren ,Cardiovascular risk ,Lifestyle ,medicine.disease ,Weight Lo ,Diet ,Candesartan ,Cerebrovascular Disorders ,Sexual Dysfunction, Physiological ,Blood pressure ,chemistry ,Heart failure ,Hyperglycemia ,Smoking Cessation ,Telmisartan ,business ,Delivery of Health Care ,Risk Reduction Behavior ,Medical Informatics ,Platelet Aggregation Inhibitors ,Contraceptives, Oral - Abstract
ABCD : Appropriate Blood pressure Control in Diabetes ABI : ankle–brachial index ABPM : ambulatory blood pressure monitoring ACCESS : Acute Candesartan Cilexetil Therapy in Stroke Survival ACCOMPLISH : Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE : angiotensin-converting enzyme ACTIVE I : Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ADVANCE : Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation AHEAD : Action for HEAlth in Diabetes ALLHAT : Antihypertensive and Lipid-Lowering Treatment to Prevent Heart ATtack ALTITUDE : ALiskiren Trial In Type 2 Diabetes Using Cardio-renal Endpoints ANTIPAF : ANgioTensin II Antagonist In Paroxysmal Atrial Fibrillation APOLLO : A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People ARB : angiotensin receptor blocker ARIC : Atherosclerosis Risk In Communities ARR : aldosterone renin ratio ASCOT : Anglo-Scandinavian Cardiac Outcomes Trial ASCOT-LLA : Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm ASTRAL : Angioplasty and STenting for Renal Artery Lesions A-V : atrioventricular BB : beta-blocker BMI : body mass index BP : blood pressure BSA : body surface area CA : calcium antagonist CABG : coronary artery bypass graft CAPPP : CAPtopril Prevention Project CAPRAF : CAndesartan in the Prevention of Relapsing Atrial Fibrillation CHD : coronary heart disease CHHIPS : Controlling Hypertension and Hypertension Immediately Post-Stroke CKD : chronic kidney disease CKD-EPI : Chronic Kidney Disease—EPIdemiology collaboration CONVINCE : Controlled ONset Verapamil INvestigation of CV Endpoints CT : computed tomography CV : cardiovascular CVD : cardiovascular disease D : diuretic DASH : Dietary Approaches to Stop Hypertension DBP : diastolic blood pressure DCCT : Diabetes Control and Complications Study DIRECT : DIabetic REtinopathy Candesartan Trials DM : diabetes mellitus DPP-4 : dipeptidyl peptidase 4 EAS : European Atherosclerosis Society EASD : European Association for the Study of Diabetes ECG : electrocardiogram EF : ejection fraction eGFR : estimated glomerular filtration rate ELSA : European Lacidipine Study on Atherosclerosis ESC : European Society of Cardiology ESH : European Society of Hypertension ESRD : end-stage renal disease EXPLOR : Amlodipine–Valsartan Combination Decreases Central Systolic Blood Pressure more Effectively than the Amlodipine–Atenolol Combination FDA : U.S. Food and Drug Administration FEVER : Felodipine EVent Reduction study GISSI-AF : Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation HbA1c : glycated haemoglobin HBPM : home blood pressure monitoring HOPE : Heart Outcomes Prevention Evaluation HOT : Hypertension Optimal Treatment HRT : hormone replacement therapy HT : hypertension HYVET : HYpertension in the Very Elderly Trial IMT : intima-media thickness I-PRESERVE : Irbesartan in Heart Failure with Preserved Systolic Function INTERHEART : Effect of Potentially Modifiable Risk Factors associated with Myocardial Infarction in 52 Countries INVEST : INternational VErapamil SR/T Trandolapril ISH : Isolated systolic hypertension JNC : Joint National Committee JUPITER : Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin LAVi : left atrial volume index LIFE : Losartan Intervention For Endpoint Reduction in Hypertensives LV : left ventricle/left ventricular LVH : left ventricular hypertrophy LVM : left ventricular mass MDRD : Modification of Diet in Renal Disease MRFIT : Multiple Risk Factor Intervention Trial MRI : magnetic resonance imaging NORDIL : The Nordic Diltiazem Intervention study OC : oral contraceptive OD : organ damage ONTARGET : ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial PAD : peripheral artery disease PATHS : Prevention And Treatment of Hypertension Study PCI : percutaneous coronary intervention PPAR : peroxisome proliferator-activated receptor PREVEND : Prevention of REnal and Vascular ENdstage Disease PROFESS : Prevention Regimen for Effectively Avoiding Secondary Strokes PROGRESS : Perindopril Protection Against Recurrent Stroke Study PWV : pulse wave velocity QALY : Quality adjusted life years RAA : renin-angiotensin-aldosterone RAS : renin-angiotensin system RCT : randomized controlled trials RF : risk factor ROADMAP : Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention SBP : systolic blood pressure SCAST : Angiotensin-Receptor Blocker Candesartan for Treatment of Acute STroke SCOPE : Study on COgnition and Prognosis in the Elderly SCORE : Systematic COronary Risk Evaluation SHEP : Systolic Hypertension in the Elderly Program STOP : Swedish Trials in Old Patients with Hypertension STOP-2 : The second Swedish Trial in Old Patients with Hypertension SYSTCHINA : SYSTolic Hypertension in the Elderly: Chinese trial SYSTEUR : SYSTolic Hypertension in Europe TIA : transient ischaemic attack TOHP : Trials Of Hypertension Prevention TRANSCEND : Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease UKPDS : United Kingdom Prospective Diabetes Study VADT : Veterans' Affairs Diabetes Trial VALUE : Valsartan Antihypertensive Long-term Use Evaluation WHO : World Health Organization ### 1.1 Principles The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology …
- Published
- 2013
- Full Text
- View/download PDF
14. Comparison of Blood Pressure Variability between 24 h Ambulatory Monitoring and Office Blood Pressure in Diabetics and Nondiabetic Patients: A Cross-Sectional Study
- Author
-
Ana Lídia Rouxinol-Dias, Marta Lisandra Gonçalves, Diogo Ramalho, Jose Silva, Loide Barbosa, and Jorge Polónia
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background. Evidence regarding blood pressure (BP) variability (BPV) and its independent association with adverse outcomes has grown. Diabetic patients might have increased BPV, but there is still an evidence gap regarding relation between BPV and type 2 diabetes beyond mean values of BP. Objective. To examine the relationship between 24 h ambulatory BP monitoring (ABPM, short-term variability) and visit-to-visit in-office BPV (OBP, long-term variability), in diabetics (D) and nondiabetics (ND), and to explore BPV relation with estimated glomerular filtration rate (eGFR), and pulse wave velocity (PWV) as indicators of target organ lesion. Materials and Methods. We conducted a single-center cross-sectional study in an outpatient BP unit, including adult patients consecutively admitted from 1999 to 2019. Multivariate was performed to compare BPV between D and ND adjusted for clinical variables. Pearson’s correlation was performed to evaluate relation of BPV with eGFR and PWV. Results. A total of 1123 patients with ABPM and OBP measurements were included. Values of eGFR and PWV were worse in D than in ND. Measurements of OBPV did not differ between groups. Of ABPM BPV, the coefficient of variation and standard deviation for daytime systolic BP were higher in D compared to ND, but only in ND did BPV correlated with both eGFR and PWV. Conclusion. We found that diabetes is associated with higher variability of daytime BP than nondiabetics along with worse damage of vascular and renal function. However, in contrast to nondiabetics, in diabetics eGFR and PWV may not be dependent on BP variability, suggesting that other mechanisms might explain more rigorously the greater damage of target organ lesion markers.
- Published
- 2022
- Full Text
- View/download PDF
15. Farmacovigilância das Vacinas contra a COVID-19 Durante a Gravidez e a Amamentação
- Author
-
Ana Marta Silva, Inês Ribeiro-Vaz, Renato Ferreira-da-Silva, Ricardo Cruz-Correia, Jorge Polónia, and João Bernardes
- Subjects
Amamentação ,Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos ,Farmacovigilância ,Gravidez ,SARS-CoV-2 ,Vacinas contra a COVID-19 ,Medicine ,Medicine (General) ,R5-920 - Abstract
N/a.
- Published
- 2021
- Full Text
- View/download PDF
16. Accuracy of twenty-four-hour ambulatory blood pressure monitoring (night-day values) for the diagnosis of secondary hypertension
- Author
-
Jorge Polonia, Ar, Santos, Gm, Gama, and Barros H
- Subjects
Adult ,Male ,Adolescent ,Hypertension ,Humans ,Female ,Prospective Studies ,Blood Pressure Monitoring, Ambulatory ,Middle Aged ,Sensitivity and Specificity ,Aged ,Circadian Rhythm ,Retrospective Studies - Abstract
To determine the accuracy of 24-h ambulatory blood pressure monitoring, using the relationship between night-time and daytime values, in diagnosing secondary hypertension.A prospective study was performed in a referred population of 402 hypertensive patients (clinic systolic/diastolic blood pressure140/90 mmHg). The ambulatory monitoring data included 24-h mean, awake (daytime) and sleeping (night-time) values. Secondary hypertension was diagnosed by standard procedures. To describe the accuracy of ambulatory blood pressure monitoring, receiver-operator characteristic curves were constructed, using sensitivity and specificity values for deciles of the distribution of overnight blood pressure falls (absolute and percentage). Measurements included the fall in nocturnal blood pressure, sensitivity (the percentage of those with secondary hypertension who were classified as non-dippers), specificity (the percentage of non-secondary hypertensives who were classified as dippers) and predictive values of ambulatory blood pressure monitoring.On average, overnight systolic/diastolic blood pressure fell in primary hypertensives (n = 290) by 20/18 mmHg (13%/19%), in white-coat hypertensives (n = 65, daytime ambulatory blood pressure135/87 mmHg) by 17/15 mmHg (13%/19%) and in patients with secondary hypertension (n = 47, renal/renovascular and endocrine forms) by 13/11 mmHg (9%/12%). From receiver-operator characteristic curves, the nocturnal blood pressure fall of 15 mmHg showed the highest accuracy, with a sensitivity/specificity of 61%/69% (systolic) and 75%/62% (diastolic) whereas 10% (systolic) and 15% (diastolic) nocturnal falls had a sensitivity/specificity of 62%/74% (systolic) and 62%/70% (diastolic). The ambulatory blood pressure data had a high (93%) negative predictive value for secondary hypertension.Secondary hypertension is associated with a blunted nocturnal fall in blood pressure. Ambulatory blood pressure monitoring data are not critically important for the diagnosis and screening of secondary hypertension but may be helpful in excluding it.
- Published
- 1995
17. Neurovascular Coupling Is Impaired in Hypertensive and Diabetic Subjects Without Symptomatic Cerebrovascular Disease
- Author
-
Ana Monteiro, Pedro Castro, Gilberto Pereira, Carmen Ferreira, Farzaneh Sorond, Andrew Milstead, James P. Higgins, Jorge Polónia, and Elsa Azevedo
- Subjects
hypertension ,diabetes mellitus ,neurovascular coupling (NVC) ,transcranial doppler (TCD) ,cerebral small vessel disease ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
The mechanistic link between hypertension, diabetes and cerebral small vessel disease (CSVD) is still poorly understood. We hypothesized that hypertension and diabetes could impair cerebrovascular regulation prior to irreversibly established cerebrovascular disease. In this study, 52 hypertensive patients [54% males; age 64 ± 11 years; 58% with comorbid diabetes mellitus (DM)] without symptomatic cerebrovascular disease underwent transcranial Doppler (TCD) monitoring in the middle (MCA) and posterior (PCA) cerebral arteries, to assess vasoreactivity to carbon dioxide (VRCO2) and neurovascular coupling (NVC). 1.5T magnetic resonance imaging was also performed and white matter hyperintensity volume was automatically segmented from FLAIR sequences. TCD data from 17 healthy controls were obtained for comparison (47% males; age 60 ± 16 years). Hypertensive patients showed significant impairment of NVC in the PCA, with reduced increment in cerebral blood flow velocity during visual stimulation (22.4 ± 9.2 vs. 31.6 ± 5.7, p < 0.001), as well as disturbed NVC time-varying properties, with slower response (lower rate time: 0.00 ± 0.02 vs. 0.03 ± 6.81, p = 0.001), and reduced system oscillation (reduced natural frequency: 0.18 ± 0.08 vs. 0.22 ± 0.06, p < 0.001), when compared to controls. VRCO2 remained relatively preserved in MCA and PCA. These results were worse in hypertensive diabetic patients, with lower natural frequency (p = 0.043) than non-diabetic patients. White matter disease burden did not predict worse NVC. These findings suggest that hypertensive diabetic patients may have a precocious impairment of NVC, already occurring without symptomatic CSVD. Future research is warranted to evaluate whether NVC assessment could be useful as an early, non-invasive, surrogate marker for CSVD.
- Published
- 2021
- Full Text
- View/download PDF
18. Avaliação da Problemática da Doença Renal Crónica (Não Diálise) em Portugal: Abordagens para a Intervenção Precoce e Redução da Progressão
- Author
-
Aníbal Ferreira, João Raposo, João Rocha, Jorge Polónia, José Cabrita, Nuno Jacinto, Patrícia Branco, Rita Birne, Margarida Maia, and Ana Marcelo
- Subjects
Glucosídeos/uso terapêutico ,Inibidores do Transportador 2 de Sódio-Glicose/uso terepêutico ,Insuficiência Renal Crónica/prevenção e controlo ,Insuficiência Renal Crónica/tratamento farmacológico ,Portugal ,Therapeutics. Pharmacology ,RM1-950 - Abstract
A doença renal crónica constitui um problema de saúde pública a nível global, estando associada a um aumento do risco da ocorrência de eventos cardiovasculares graves e aumento da mortalidade. Sendo Portugal um dos países europeus com maior incidência desta patologia, salientamos a importância de promover um aumento da notoriedade deste tema junto das autoridades de saúde, dos profissionais de saúde e da comunidade científica. Apresentamos algumas recomendações que consideramos relevantes para a melhor gestão desta problemática no nosso país, nomeadamente a promoção da comunicação entre diferentes especialidades médicas, organização dos cuidados e referimos outras que podem futuramente vir a desempenhar um papel importante na abordagem terapêutica, como os inibidores do co-transportador de sódio e glucose 2, na redução da morbilidade e mortalidade desta população.
- Published
- 2021
- Full Text
- View/download PDF
19. A evolução histórica do envolvimento dos sistemas neuro‐humorais no conhecimento da fisiopatologia e do tratamento da insuficiência cardíaca
- Author
-
Jorge Polónia and Francisco Rocha Gonçalves
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Resumo: Nos anos 1980 assistiu‐se a uma evolução profunda do conhecimento sobre a fisiopatologia da insuficiência cardíaca (IC): outrora considerada uma síndrome clínica de origem fundamentalmente estrutural, a IC começou a ser vista como a consequência de um desequilíbrio de forças hormonais opostas. Foi, de facto, nesta década que surgiram os estudos basilares sobre o impacto dos sistemas neuro‐hormonais na IC. E destes destacam‐se oito: quatro de natureza vasoconstritora e antinatriurética (o sistema nervoso simpático [SNS], o sistema da renina‐angiotensina‐aldosterona [SRAA], o sistema da vasopressina arginina e a endotelina) e quatro de natureza vasodilatadora e natriurética (o sistema das protaglandinas [PGs], do óxido nítrico [NO], o sistema dopaminérgico e o sistema dos péptidos natriuréticos [NPS]). Fortemente interligados entre si e com um sistema de regulação intrincado, estes sistemas funcionam habitualmente numa homeostasia delicada, cuja disrupção é sinal característico da IC. Nesta revisão é explorado o desenvolvimento histórico do conhecimento sobre o impacto destes sistemas neuro‐hormonais na IC desde os seus primeiros estudos até ao conhecimento atual. Para além disso, são também revisitadas as oportunidades terapêuticas que cada um deles apresenta, bem como as famílias de antagonistas neuro‐hormonais atualmente utilizadas na terapia da IC. Nesta última parte dá‐se especial destaque ao último fármaco aprovado para utilização em doentes com IC com fração de ejeção reduzida, o sacubitril/valsartan, que combina dois antagonistas e que por isso atua simultaneamente em dois sistemas neuro‐hormonais: o SRAA e o NPS. Abstract: Our knowledge of the pathophysiology of heart failure (HF) underwent profound changes during the 1980s. Once thought to be of exclusively structural origin, HF began to be seen as the consequence of hormonal imbalance. A number of seminal studies were published in that decade focusing on the impact of neurohormonal activation in HF. Presently, eight neurohormonal systems are known to have a key role in HF development: four stimulate vasoconstriction and sodium/water retention (the sympathetic nervous system, the renin‐angiotensin‐aldosterone system [RAAS], endothelin, and the vasopressin‐arginine system), while the other four stimulate vasodilation and natriuresis (the prostaglandin system, nitric oxide, the dopaminergic system, and the natriuretic peptide system [NPS]). These systems are strongly interconnected and are subject to intricate regulation, functioning together in a delicate homeostasis. Disruption of this homeostasis is characteristic of HF. This review explores the historical development of knowledge on the impact of the neurohormonal systems on HF pathophysiology, from the first studies to current understanding. In addition, the therapeutic potential of each of these systems is discussed, and currently used neurohormonal antagonists are characterized. Special emphasis is given to the latest drug approved for use in HF with reduced ejection fraction, sacubitril/valsartan. This drug combines two different molecules, acting on two different systems (RAAS and NPS) simultaneously. Palavras‐chave: Insuficiência cardíaca, Sistemas neuro‐hormonais, Antagonistas neuro‐hormonais, Sacubitril/valsartan, Keywords: Heart failure, Neurohormonal systems, Neurohormonal antagonists, Sacubitril/valsartan
- Published
- 2019
- Full Text
- View/download PDF
20. Efeito da empagliflozina para além do controlo glicémico: benefício cardiovascular em doentes com DMT2 e doença cardiovascular estabelecida
- Author
-
Pedro Monteiro, Carlos Aguiar, Pedro Matos, José Silva‐Nunes, Rita Birne, Patrícia Branco, Joaquim Calado, Miguel Melo, and Jorge Polónia
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Resumo: A prevalência da diabetes mellitus tipo 2 (DMT2) continua a aumentar e a sua associação com a doença cardiovascular (CV) tem levado à incorporação e valorização de endpoints CV nos ensaios clínicos sobre o tratamento da DMT2.Este artigo faz uma revisão dos vários ensaios já realizados e em desenvolvimento, neste âmbito, com especial enfoque no estudo EMPA‐REG OUTCOME. Neste estudo, a empagliflozina, um inibidor do cotransportador tipo 2 de sódio/glicose (iSGLT2), demonstrou efeitos benéficos na redução do risco CV em doentes com DMT2 e doença CV estabelecida, para além de segurança CV e diminuição dos valores de HbA1c, representando uma mudança de paradigma com impacto ao nível das recomendações internacionais para o tratamento da DMT2. Estes resultados mantiveram‐se em análises de subgrupos posteriores, nomeadamente na insuficiência cardíaca, doença renal crónica e doença arterial periférica, ainda que muitas questões se coloquem sobre os mecanismos envolvidos nestes efeitos – se efeitos hemodinâmicos, efeitos metabólicos ou se a diminuição das concentrações de sódio citoplasmático no miocárdio.Com a diminuição do risco de eventos CV major em doentes com DMT2, os resultados do estudo EMPA‐REG OUTCOME demonstraram, pela primeira vez, proteção CV associada ao efeito de um fármaco anti‐hiperglicémico e iniciaram uma nova era no tratamento e gestão da DMT2. Este estudo levou ao desenvolvimento de outros ensaios, ainda a decorrer, que permitirão estabelecer quais os doentes que mais beneficiarão desta terapêutica, nomeadamente na relação à existência de comorbilidades. Abstract: The prevalence of type 2 diabetes (T2D) continues to increase, and its association with cardiovascular (CV) disease has led to the inclusion of CV endpoints in clinical trials on the treatment of T2D.This article explores the various trials already performed and under development in this field, with particular focus on the EMPA‐REG OUTCOME trial. In this trial, empagliflozin, a sodium‐glucose co‐transporter 2 inhibitor, demonstrated a reduction in CV risk in patients with T2D and established CV disease, in addition to CV safety and a decrease in glycated hemoglobin. This represents a paradigm shift that has led to changes in the international guidelines for the treatment of T2D. These results were maintained in subsequent subgroup analysis for heart failure, chronic kidney disease and peripheral arterial disease, although there are many questions concerning the mechanisms involved in these effects, including whether they are hemodynamic, metabolic or due to decreased myocardial cytoplasmic sodium concentrations.With this reduction in risk for major CV events in patients with T2D, the EMPA‐REG OUTCOME trial demonstrated CV protection from a hypoglycemic drug for the first time, and opened a new era in the treatment and management of T2D. This study has led to the development of ongoing trials that will establish which patients will benefit most from this therapy, particularly with regard to comorbidities. Palavras‐chave: Empagliflozina, Diabetes, Doença cardiovascular, Insuficiência cardíaca, Keywords: Empagliflozin, Diabetes, Cardiovascular disease, Heart failure
- Published
- 2019
- Full Text
- View/download PDF
21. Assessment of cardiovascular risk and social framework of Cape Verdean university students studying in Portugal
- Author
-
Liliana Tavares, Conceição Calhau, and Jorge Polónia
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Introduction: The migration of African populations to Europe poses problems of adaptation that may increase the risk of cardiovascular disease. We assessed the cardiovascular risk of Cape Verdean university students studying in Portugal (CV-PT) compared to Cape Verdean university students in Cape Verde (CV-CV) and to Caucasian university students in Portugal (PT-PT). Methods: A cross-sectional study was performed comparing three university populations, 54-62% female, aged 19-28 years: CV-PT (n=104), CV-CV (n=100) and PT-PT (n=100). Anthropometric data, blood pressure (BP), pulse wave velocity (PWV), albuminuria and estimated 24-h urinary sodium excretion (UNa+) using the Kawasaki formula were measured. Results: The CV-PT group had higher body mass index and sodium intake (UNa+: CV-PT 235±91, CV-CV 197±85, PT-PT 194±90 mmol/24 h; p
- Published
- 2018
- Full Text
- View/download PDF
22. Ambulatory blood pressure monitoring profiles in a cross-sectional analysis of a large database of normotensive and true or suspected hypertensive patients
- Author
-
Sara Araújo, Ana Rouxinol-Dias, José Mesquita-Bastos, José Silva, Loide Barbosa, and Jorge Polónia
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Objective: To assess ambulatory blood pressure monitoring (ABPM) circadian patterns and their determinants in a large sample of normotensive and hypertensive patients. Methods: A total of 26 170 individual ABPM recordings from 1995 to 2015 were analyzed. Mean office blood pressure (OBP), 24-hour blood pressure (BP), daytime BP and nocturnal BP were measured. Circadian patterns were classified by nocturnal systolic BP fall as extreme dipper (ED, ≥20%), dipper (D, 10%-19.9%), non-dipper (ND, 0%-9.9%), and reverse dipper (RD, 30 kg/m2 vs. others (46.5 vs. 42.9%, p43%, including in NT. Age and BMI predicted non-dipping. Resumo: Objetivo: Avaliar os perfis circadiários da pressurometria ambulatória 24 h (ABPM) numa vasta população de normotensos e hipertensos. Métodos: Analisaram-se 26 170 registos de ABPM (1995-2015). Avaliou-se a pressão arterial (BP) de consultório (cBP), diurna (dayBP), noturna (nightBP) e de 24-horas (24hBP). Perfis circadiários definidos pela queda percentual noturna (Nqueda %) da pressão sistólica (SBP): extreme dipper (ED>=20%), dipper (D, 10%-19,9%), non-dipper (ND 0%-9,9%) e reverted dipper (RD =65 versus < 65 anos (54,9 versus 33,1%, p
- Published
- 2018
- Full Text
- View/download PDF
23. Long-Term Risk of Progression to Sustained Hypertension in White-Coat Hypertension with Normal Night-Time Blood Pressure Values
- Author
-
João Faria, José Mesquita Bastos, Susana Bertoquini, José Silva, and Jorge Polónia
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background. The long-term prognosis and transition towards sustained ambulatory hypertension (SHT) of white-coat hypertension (WCHT) remain uncertain particularly in those with both normal nighttime and daytime blood pressure (BP) values. Different classification criteria and the use of antihypertensive drugs may contribute to conflicting results. Patients and Methods. We prospectively evaluated for a 7.1 year transition to SHT in 899 nondiabetic subjects free from cardiovascular (CV) events: normotensive (NT) (n = 344; 52, 9% female; ageing 48 ± 14 years); untreated WCHT (UnWCHT n = 399; 50, 1% female; ageing 51 ± 14 years); and treated WCHT with antihypertensive drugs after baseline (TxWCHT n = 156; 54, 4% female; ageing 51 ± 15 years). All underwent 24 h ambulatory BP monitoring (24 h-ABPM) at baseline, at 30 to 60 months, and at 70 to 120 months thereafter. WCHT was at baseline (with no treatment) as office BP ≥ 140/or 90 mm·Hg, daytime BP
- Published
- 2020
- Full Text
- View/download PDF
24. Os valores da pressão arterial aórtica e índice de aumentação central em indivíduos com hipertensão da bata branca são mais próximos dos indivíduos normotensos do que dos hipertensos tratados para idênticas idades, género e pressão noturna
- Author
-
Joana Almeida, José Monteiro, José A. Silva, Susana Bertoquini, and Jorge Polónia
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Resumo: Introdução: Permanece controverso se os indivíduos com hipertensão da bata branca (HBBs) exibem alterações hemodinâmicas e estruturais diferentes dos indivíduos normotensos (NTs) e hipertensos (HTs). Métodos: Comparamos marcadores de prognóstico cardiovascular (CV): velocidade da onda de pulso (VOP), índice rigidez aórtica (AASI) e as alterações da onda de pressão aórtica (índice de aumentação [AIx], pressão de aumentação [AugP] e amplificação central periférica da pressão de pulso [PPA]) entre NTs (n = 175), HBBs (n = 315) e HTs tratados (n = 691) todos com pressão arterial (PA) de 24 h
- Published
- 2016
- Full Text
- View/download PDF
25. P30 A 12-WEEK EXERCISE TRAINING PROGRAM REDUCES ENDOTHELIAL DAMAGE IN RESISTANT HYPERTENSION
- Author
-
Susana Lopes, Catarina Garcia, Ana Gonçalves, Ilda Ribeiro, Joana Barbosa de MElo, Veronica Ribau, Daniela Figueiredo, João Viana, Susana Bertoquini, Jorge Polónia, José Mesquita-Bsstos, Alberto Alves, and Fernando Ribeiro
- Subjects
Specialties of internal medicine ,RC581-951 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background: Resistant Hypertension (RH) is associated with an increased risk of cardiovascular events and poor prognosis. Exercise training studies in RH patients have shown promising outcomes, nonetheless, none determine the impact of exercise on endothelial damage and repair. Circulating endothelial cells (CECs) are a reliable indicator of vascular damage and dysfunction. Recent studies in hypertension suggest that increased levels of endothelial progenitor cells (EPCs), a marker of endothelial repair, are related to increased CECs in order to compensate endothelial damage. Purpose: This study aimed to determine the effect of 12-week aerobic exercise program on the percentage of EPCs and CECs in RH patients. Methods: Patients with RH were randomized to a 12-week aerobic exercise program (3 xs/week) (n = 13) and a usual care control group (n = 8). Outcome measures included clinical data, ambulatory blood pressure data and circulating levels of EPCs, hematopoietic stem cells (HSC) and CECs, quantified by flow cytometry. (ClinicalTrials.gov: NCT03090529). Results: Baseline characteristics were similar between groups, including the number of antihypertensive drugs (5.0 ± 0.9 vs. 4.8 ± 0.7, p = 0.517). After 12 weeks, no significant changes were found in the levels of HSCs in both groups. The levels of CECs decreased in the exercise group [0.0073 (0.0016)% to 0.0058 (0.0029), p = 0.019]; no changes were observed in the control group. EPC’s decreased only in the exercise group [0.0071 (0.0027)% to 0.0052 (0.0037)%, p = 0.046]. Conclusions: Exercise training reduces endothelial injury/damage (reduced CECs levels) in RH patients, a specific group who is a challenge for clinicians as the available treatment options have reduced success.
- Published
- 2018
- Full Text
- View/download PDF
26. P121 ASSOCIATION OF CARDIORESPIRATORY FITNESS WITH ARTERIAL STIFFNESS AND PERIPHERAL AND CENTRAL BLOOD PRESSURE IN RESISTANT HYPERTENSION PATIENTS
- Author
-
Catarina Garcia, Susana Lopes, Susana Bertoquini, Verónica Ribau, Cátia Leitão, Daniela Figueiredo, Ilda P Ribeiro, Joana Barbosa de Melo, João L Viana, José Mesquita-Bastos, Jorge Polónia, Fernando Ribeiro, and Alberto J Alves
- Subjects
Specialties of internal medicine ,RC581-951 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background: The relationship between arterial stiffness, blood pressure (BP) and cardiorespiratory fitness (CRF) has been studied in healthy populations and cardiovascular patients, since all of which proved to be independent predictors of all-cause mortality. We aimed to investigate the association of CRF with arterial stiffness and peripheral and central hemodynamics, in patients with resistant hypertension (RT). Methods: In this cross-sectional study, 30 patients (13 men, 17 women; age, 57.7 ± 8.1 years; weight, 79.2 ± 11.6 kg; body mass index, 29.7 ± 4.0 kg/m2) with resistant hypertension were recruited in the Hospital Infante D. Pedro (Aveiro) and Hospital Pedro Hispano (Matosinhos). Outcome measures included CRF (VO2peak), peripheral and central BP, and carotid-femoral pulse wave velocity (cf-PWV). Correlation analysis was conducted to assess the association between variables. Results: A significant negative correlation was found between VO2peak (33.7 ± 6.2 mLO2/kg/min) and central (141.0±21.3 mmHg; r = −0.395, p = 0.031) and peripheral systolic BP (148.4 ± 21.3 mmHg; r = −0.363, p = 0.049). VO2peak was also correlated with pulse pressure (PP) amplification ratio (1.2 ± 0.1 mmHg; r = 0.361, p = 0.050). The association with central systolic BP (r = −0.403, p = 0.035) and PP amplification ratio (r = 0.408, p = 0.033) remained significant after adjusted for age. VO2peak showed no correlation with PWV (9.4 ± 2.9 m/s; r = −0.075, p = 0.694) and peripheral (88.1 ± 12.2 mmHg; r = −0.138 p = 0.467) and central diastolic BP (88.5 ± 12.7 mmHg; r = −0.133, p = 0.483). Conclusion: This study confirms the inverse relationship between CRF and central systolic BP and PP amplification ratio in RH patients, regardless of age.
- Published
- 2018
- Full Text
- View/download PDF
27. P154 DOES THE METHOD OF THE MEASUREMENT OF BLOOD PRESSURE CORRELATES DIFFERENTLY WITH PULSE WAVE VELOCITY IN RESISTANT HYPERTENSION?
- Author
-
Jose Mesquita Bastos, Susana Lopes, Catarina Garcia, Verónica Ribau, Susana Bertoquini, Cátia Leitão, P. Ribeiro Ilda, Daniela Figueiredo, L. Viana João, Fernando Ribeiro, and Jorge Polónia
- Subjects
Specialties of internal medicine ,RC581-951 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Objective: Carotid-femoral Pulse Wave velocity (cfPWV), the gold standard for measuring stiffness, is a marker of organ damage (OLD). Even though cfPWV correlates with casual (BPc), central (CBP) and ambulatory (ABPM) blood pressure (BP), evidence is limited for resistant hypertension (RH). Method: Thirty-three patients (age, 56.1 ± 8.2 years; weight, 78.0 ± 12.4 kg; height, 1.62 ± 0.08 m) with RH participated in a cross-sectional study. Outcomes included clinical data, BPc, ABPM, and carotid-femoral, cfPWV. Correlation analysis was conducted to assess the association between variables; independent t-tests were conducted to compare variables between those participants with cfPWV < and ≥ 10 m/s. Results: Patients (20 women and 13 men) presented a peripheral systolic and diastolic BPc of 144.0 ± 3.8 mmHg and 82.0 ± 1.9 mmHg, respectively. The cfPWV correlated with age (r = 0.356, p = 0.045), 24 h systolic BP (24 h SBP) nightime pulse pressure (night PP), 24 h pulse pressure (24hPP), casual systolic (SBPc) and diastolic BP (DBPc), central systolic (CSBP), diastolic (CDBP) and central pulse pressure (CPP); controlled for age the correlation remained significant for 24h SBP (r=0.446, p=0.009) 24hPP (r=0.464, p=0.007), nightPP (r=0.365, p=0.036), SBPc (r=0.620, p
- Published
- 2018
- Full Text
- View/download PDF
28. Reprodutibilidade dos valores da pressurometria ambulatória de 24 horas e dos perfis circadiários de descida noturna registados com intervalo 1‐11 meses em indivíduos não medicados
- Author
-
Miguel Monte, Mariana Cambão, José Mesquita Bastos, and Jorge Polónia
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Resumo: Introdução: Avaliar em indivíduos não medicados a reprodutibilidade dos valores médios e dos quatro perfis circadiários entre dois registos de pressurometria ambulatória de 24 horas (MAPA) separados de 1‐11 meses. Métodos: Análise retrospetiva de 481 indivíduos (59% mulheres) avaliados por MAPA em dois dias, visita um (V1) e visita dois (V2) separados por 5,5 + 0,2 meses. Perfis circadiários definidos pelos ratios noite/dia da pressão sistólica (PAS) em: reverted dippers, RD se ratio > 1,0, non‐dippers, ND se ratio 0,9‐ 1.0; non‐dippers (ND), ratio 0.9‐1.0; dippers (D), ratio 0.8‐
- Published
- 2015
- Full Text
- View/download PDF
29. Prevalência da microalbuminúria em doentes hipertensos e/ou diabéticos tipo 2 nos Cuidados de Saúde Primários em Portugal: Estudo RACE (micRoAlbumin sCreening survEy)
- Author
-
Pedro Marques da Silva, Davide Carvalho, José Nazaré, Luís Martins, Carlos Aguiar, Maria Conceição Manso, Teresa Carqueja, and Jorge Polónia
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Resumo: Introdução e objetivos: Determinar a prevalência de microalbuminúria (MAU) em doentes hipertensos (HTA) e/ou diabéticos tipo 2 (DM2) e em normotensos não diabéticos (grupo controlo). Como objetivos secundários, analisar as diferenças de distribuição da MAU nas quatro subpopulações e observar a associação de variáveis clínicas e epidemiológicas diversas com a MAU. Métodos: O RACE (micRoAlbuminsCreeningsurvEy) é um estudo epidemiológico descritivo, observacional de corte transversal, multicêntrico, que incluiu doentes acompanhados nos Cuidados de Saúde Primários (CSP) em Portugal. Os doentes com causas potenciais de falsos positivos para MAU foram excluídos. As avaliações principais foram a frequência da MAU, determinada pelo teste da tira reativa Micral‐Test®, a pressão arterial (PA), as variáveis demográficas, as doenças concomitantes, a medicação cardiovascular e antidiabética e as variáveis bioquímicas. Resultados: Um total de 9198 participantes (3769 hipertensos, 3100 diabéticos tipo 2 hipertensos, 423 diabéticos normotensos e 1906 controlos), 54,7% do sexo feminino, foram incluídos na análise primária. A prevalência de MAU foi de 58% nos doentes com HTA + DM2, 51% nos doentes com DM2, 43% nos doentes com HTA e de 12% no grupo controlo (χ2: p
- Published
- 2015
- Full Text
- View/download PDF
30. Neutrophil-to-lymphocyte ratio and ambulatory blood pressure: Exploring the link between inflammation and hypertension
- Author
-
Jorge Polónia
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2017
- Full Text
- View/download PDF
31. Avaliação das propriedades dinâmicas da pressão arterial em mulheres com antecedentes de pré‐eclâmpsia
- Author
-
Jorge Polónia, Catarina Olival, Sílvia Ribeiro, José A. Silva, and Loide Barbosa
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Resumo: Objetivo: Investigar alterações hemodinâmicas e das propriedades viscoelásticas da parede arterial em mulheres com prévia pré‐eclâmpsia (PE) versus mulheres com antecedentes de gravidezes normais (NT). Métodos: Estudo transversal em mulheres, 45 com prévia PE e 55 NT, emparelhadas para idade: PE: 38 ± 6 versus NT: 38 ± 5 anos, n.s., índice massa PE: 25 ± 4 versus NT: 26 ± 4 kg/m2, n.s, e 76 ± 34 (NT) e 86 ± 48 (PE) meses após o parto. Avaliamos rigidez arterial – velocidade onda pulso (PWV, Complior) e ondas refletidas (pressão de aumentação AP) e índice de aumentação (AIx,%) na onda de pressão central e a pressão arterial de 24 horas (MAPA). Resultados: PE apresentaram pressão sistólica (PAS) periférica PE: 131 ± 18 versus NT: 121 ± 19 e PAS central PE: 122 ± 18 versus NT: 110 ± 19 mais elevadas (p
- Published
- 2014
- Full Text
- View/download PDF
32. A Diabetes Mellitus em Portugal: Relevância da Terapêutica Farmacológica Adequada
- Author
-
Armando Brito de Sá, Catarina Oliveira, Davide Carvalho, João Raposo, Jorge Polónia, José Aranda da Silva, José Luís Medina, Luís Gardete Correia, Luís Silva Miguel, and Rui Cernadas
- Subjects
Therapeutics. Pharmacology ,RM1-950 - Abstract
A diabetes representa um sério e grave problema de saúde pública em Portugal, onde se estima que a prevalência desta patologia na população com idades compreendidas entre os 20 e os 79 anos seja de 13,1%, o que equivale a mais de um milhão de indivíduos diabéticos. A diabetes é uma patologia com importantes e graves implicações sociais, económicas e humanas. De facto, estima-se que os custos com esta patologia em Portugal representem aproximadamente 10% da despesa total em Saúde e 0,9% do PIB português. Em particular, registou-se nos últimos anos um aumento significativo dos encargos com os medicamentos antidiabéticos, decorrente, em grande medida, da recente introdução no mercado de novas classes terapêuticas que apresentam um custo elevado. Por estes motivos, facilmente se compreende que a diabetes representa uma séria ameaça à sustentabilidade financeira dos sistemas de saúde. O tema “A Diabetes em Portugal” foi objeto de uma reunião de reflexão, a qual teve como propósito debater as implicações socioeconómicas da diabetes, o papel dos antidiabéticos orais numa perspetiva holística da abordagem terapêutica desta patologia, a atualidade das normas de orientação clínica e a sua aplicabilidade na prática clínica, tendo em consideração as características específicas de cada doente e ainda estratégias que permitam garantir o acesso dos doentes às novas terapêuticas. Os especialistas que participaram nesta reunião expressaram, de forma consensual, a necessidade de serem implementados programas de prevenção da diabetes efetivos e direcionados para a população. Pese embora o facto de estes programas implicarem um investimento inicial significativo, a prevenção ou retardamento da progressão da doença tem um impacto substancial na saúde global da população e o potencial de gerar poupanças consideráveis para o sistema de saúde. O tratamento da Diabetes deve ser individualizado e centrado no doente, com o objetivo de incrementar a efetividade da terapêutica e de otimizar os resultados a longo prazo. As modificações do estilo de vida devem ser parte integrante de um plano terapêutico personalizado. Os doentes devem encontrar-se ativamente envolvidos na decisão do tratamento, devendo igualmente receber uma educação adequada sobre a patologia. Por fim, a prescrição de novas classes terapêuticas para a diabetes não deverá ser condicionada pelo seu custo elevado, uma vez que a escolha do tratamento deve fundamentar-se na evidência clínica e nas necessidades do doente. Contudo, as terapêuticas inovadoras acarretam um acréscimo dos encargos em Saúde, motivo, aliás, pelo qual o seu custo-efetividade é objeto de avaliação pelas entidades competentes.
- Published
- 2016
- Full Text
- View/download PDF
33. Definição de valores de referência da velocidade da onda de pulso arterial numa população portuguesa: Uma sub-análise do projecto EDIVA
- Author
-
Telmo Pereira, João Maldonado, Jorge Polónia, José Alberto Silva, João Morais, and Mário Marques
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Resumo: Introdução: A velocidade da onda de pulso carotideo-femoral (VOP) tem constituído um importante marcador de risco cardiovascular, traduzindo o reflexo arterial subsequente a um conjunto de contextos clínicos em que o impacto cardiovascular é manifesto. Este trabalho visou estabelecer parâmetros de normalidade da VOP para a população portuguesa, com base numa definição estatística. Método: O presente trabalho corresponde a uma sub-análise do Projecto EDIVA, envolvendo 668 indivíduos saudáveis (412 do sexo masculino), com idade média 39,73 ± 15,6 anos, índice de massa corporal 25,56 ± 4,05 kgm2, pressão arterial sistólica e diastólica respectivamente 125,47 ± 11,18 e 75,75 ± 9,27 mmHg. Estes indivíduos foram submetidos a um follow-up médio de 23,3 ± 3,34 meses, com avaliação anual da VOP. A normalidade foi definida em termos da história pessoal e familiar, da avaliação clínica, do ECG de superfície e da realização de exames analíticos de rotina. Resultados: A VOP média na amostra foi de 8,8 ± 1,4 m/s, sendo de 8,7 ± 1,6 m/s e 8,9 ± 1,5 m/s, respectivamente no sexo feminino e masculino (p = ns). A normalidade foi definida a partir do percentil 95 para cada faixa etária, e por género. A avaliação sequencial permitiu ainda avaliar o contributo percentual de agravamento da VOP face ao envelhecimento (5%), definindo-se assim uma variação positiva da VOP (em avaliações sequenciais) inferior a 5% como normal. Conclusão: Os resultados obtidos permitem: por um lado, estabelecer critérios de referência para a VOP tendo em consideração o papel determinante do envelhecimento na deterioração fisiológica da função das grandes artérias; por outro lado, estabelecer uma medida de valorização da variação longitudinal da VOP, aspecto que se reveste de grande importância face à adopção desta metodologia em programas integrados de seguimento de doentes com risco cardiovascular manifesto. Abstract: Introduction: Aortic pulse wave velocity (PWV) has been associated with cardiovascular risk in different clinical subsets. This subanalysis of the EDIVA project aimed to establish criteria for normality of PWV based on a statistical definition that considers the fundamental physiological role of aging in arterial stiffness. Methods: A sample of 668 healthy subjects (412 male) enrolled in the EDIVA Project (a prospective, multicenter, observational study) were studied. Mean age was 40.00 ± 13.42 years, body mass index was 25.90 ± 4.21 kg/m2, and systolic and diastolic blood pressure were respectively 125.47 ± 11.18 and 75.75 ± 9.27 mmHg. PWV was determined annually using a Complior device, and mean follow-up was 23.3 ± 3.34 months. Personal and family history, physical examination, electrocardiogram and biochemical analysis were used to determine individual health. Results: In the overall population PWV was 8.8 ± 1.4 m/sec, 8.7 ± 1.6 m/sec in men and 8.9 ± 1.5 m/sec in women (p = NS). Normal PWV was defined as the 95th percentile adjusted for age and gender, above which PWV was considered abnormal. Serial evaluation of PWV also enabled the annual age-dependent increase in PWV to be estimated at 5%, values above this cut-off being defined as abnormal vascular deterioration. Conclusion: This study establishes criteria for normality based on a statistical definition that takes into account the fundamental physiological role of aging in arterial stiffness. Additionally, it provides a cut-off for the clinical interpretation of serial PWV measurements. Palavras-chave: Velocidade da onda de pulso, Distensibilidade arterial, Normalidade, Risco cardiovascular, Keywords: Pulse wave velocity, Arterial stiffness, Normality, Reference values
- Published
- 2011
- Full Text
- View/download PDF
34. Estratégias para aumentar a sensibilidade da farmacovigilância em Portugal Estrategias para aumentar la sensibilidad de la farmacovigilancia en Portugal Strategies to increase the sensitivity of pharmacovigilance in Portugal
- Author
-
Inês Ribeiro-Vaz, Maria Teresa Herdeiro, Jorge Polónia, and Adolfo Figueiras
- Subjects
Preparaciones Farmacéuticas ,Sistemas de Registro de Reacción Adversa a Medicamentos ,Toxicidad de Medicamentos ,Estudios de Intervención ,Educación en Salud ,Vigilancia Sanitaria ,Preparações Farmacêuticas ,Sistemas de Notificação de Reações Adversas a Medicamentos ,Toxicidade de Drogas ,Estudos de Intervenção ,Educação em Saúde ,Vigilância Sanitária ,Pharmaceutical Preparations ,Adverse Drug Reaction Reporting Systems ,Drug Toxicity ,Intervention Studies ,Health Education ,Health Surveillance ,Public aspects of medicine ,RA1-1270 - Abstract
OBJETIVO: Avaliar os resultados de intervenção para melhoria da quantidade e relevância das notificações de reacções adversas a medicamentos. MÉTODOS: Foi implementado um estudo controlado aleatorizado, por agrupamentos em farmacêuticos a exercer actividade profissional na região norte de Portugal, em 2007. Após aleatorização, 364 indivíduos foram alocados ao grupo de intervenção (261 na intervenção telefónica e 103 nos workshops); o grupo de controlo foi constituído por 1.103 farmacêuticos. Na intervenção educativa foram abordados a problemática das reacções adversas a medicamentos, o impacto na saúde pública e a notificação espontânea. Quanto à relevância, as reações adversas foram classificadas em graves e inesperadas. A análise estatística foi efectuada com base no princípio intention-to-treat; aplicaram-se modelos lineares generalizados mistos, utilizando o método penalized quasi-likelihood. Os farmacêuticos estudados foram seguidos durante um período de 20 meses. RESULTADOS: A intervenção aumentou três vezes a taxa de notificação espontânea das reações adversas (RR = 3,22; IC 95%: 1,33; 7,80) relativamente ao grupo de controlo. Houve incremento da relevância das notificações com aumento das reações adversas graves em cerca de quatro vezes (RR = 3,87; IC 95%: 1,29;11,61) e inesperadas em cinco vezes (RR = 5,02; IC 95%: 1,33;18,93), relativamente ao grupo de controlo. CONCLUSÕES: As intervenções educativas aumentam significativamente, por até quatro meses, a quantidade e a relevância das notificações espontâneas de reacções adversas a medicamentos por parte dos farmacêuticos da região norte de Portugal.OBJETIVO: Evaluar los resultados de intervención para mejoría de la cantidad y relevancia de las notificaciones de reacciones adversas a medicamentos. MÉTODOS: Fue implementado un estudio controlado aleatorio, por agrupaciones de farmacéuticos que ejercen actividad profesional en la región norte de Portugal, en 2007. Posterior a la aleatoriedad, 364 individuos fueron distribuidos en el grupo de intervención (261 en la intervención telefónica y 103 en los workshops); el grupo control fue constituido por 1.103 farmacéuticos. En la intervención educativa fueron abordados la problemática de las reacciones adversas a medicamentos, el impacto en la salud pública y la notificación espontánea. Con relación a la relevancia, las reacciones adversas fueron clasificadas en graves e inesperadas. El análisis estadístico fue efectuado con base en el principio intention-to-treat; se aplicaron modelos lineares generalizados mixtos, utilizando el método penalized quasi-likelihood. Los farmacéuticos estudiados fueron seguidos durante un período de 20 meses. RESULTADOS: La intervención aumentó tres veces la tasa de notificación espontánea de las reacciones adversas (RR=3,22; IC95%:1,33;7,80) con relación al grupo control. Hubo un incremento en la relevancia de las notificaciones con aumento de las reacciones adversas graves en cerca de cuatro veces (RR=3,87; IC95%:1,29;11,61) e inesperadas en cinco veces (RR=5,02; IC 95%: 1,33;18,93), con relación al grupo control. CONCLUSIONES: Las intervenciones educativas aumentan significativamente, en hasta cuatro meses, la cantidad y la relevancia de las notificaciones espontáneas de reacciones adversas a medicamentos por parte de los farmacéuticos de la región Norte de Portugal.OBJECTIVE: To evaluate the results of an intervention to improve the number and relevance of reports of adverse drug reactions. METHODS: A cluster-randomized controlled trial was conducted with pharmacists working in Northern Portugal, in 2007. After randomization, 364 individuals were placed into the intervention group (261 in telephone interviews and 103 in workshops), while the control group was comprised of 1,103 pharmacists. The following were approached in the educational intervention: the problem of adverse drug reaction, the impact on public health and spontaneous reporting. With regard to relevance, adverse reactions were classified into severe and unexpected. Statistical analysis was performed, based on the intention-to-treat principle; generalized linear mixed models were applied, using the penalized quasi-likelihood method. The pharmacists studied were followed during a period of 20 months. RESULTS: The intervention increased the rate of spontaneous reporting of adverse reactions three times (RR = 3.22; 95% CI 1.33;7.80), when compared to the control group. The relevance of reporting rose, with an increase in severe adverse reactions by approximately four times (RR = 3.87; 95% CI 1.29;11.61) and in unexpected adverse reactions by five times (RR = 5.02; 95% CI 1.33;18.93), compared to the control group. CONCLUSIONS: During a period of up to four months, educational interventions significantly increased the number and relevance of spontaneous reporting of adverse drug reactions by pharmacists in Northern Portugal.
- Published
- 2011
35. Guiding axes for drug safety management of pharmacovigilance centres during the COVID-19 era
- Author
-
Renato Ferreira da Silva, Manuela Morato, Jorge Polonia, Inês Régio Vaz, and Inês Ribeiro-Vaz
- Subjects
Coronavirus disease 2019 (COVID-19) ,Drug-Related Side Effects and Adverse Reactions ,Pharmaceutical Science ,Pharmacy ,Context (language use) ,Toxicology ,030226 pharmacology & pharmacy ,Antiviral Agents ,Incident Reporting System ,03 medical and health sciences ,Pharmacovigilance ,0302 clinical medicine ,Pandemic ,medicine ,Adverse Drug Reaction Reporting Systems ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Adverse Drug Reaction ,Risk management ,Pharmacology ,business.industry ,SARS-CoV-2 ,COVID-19 ,Public relations ,medicine.disease ,Adverse Drug Event ,COVID-19 Drug Treatment ,Workflow ,Commentary ,Patient Safety ,Drug Monitoring ,business ,Adverse drug reaction - Abstract
The COVID-19 pandemic presents several challenges to the organisation and workflow of pharmacovigilance centres as a result of the massive increase in reports, the need for quick detection, processing and reporting of safety issues and the management of these within the context of lack of complete information on the disease. Pharmacovigilance centres permanently monitor the safety profile of medicines, ensuring risk management to evaluate the benefit-risk relationship. However, traditional pharmacovigilance approaches of spontaneous reporting, are not suitable in the context of a pandemic; the scientific community and regulators need information on a near real-time point. The aim of this commentary is to suggest six interrelated multidimensional guiding axes for drug safety management by pharmacovigilance centres during the COVID-19 pandemic. This working plan can increase knowledge on COVID-19 and associated therapeutic approaches, support decisions by the regulatory authorities, oppose fake news and promote more efficient public health protection.
- Full Text
- View/download PDF
36. Preoperative withdrawal of digitalis therapy in cardiac valve surgery. Effects on digitalization status and postoperative complications
- Author
-
Jorge Polonia, Neves, C. A., Rodrigues, M. A., Brandao, F., Guerreiro, M., Graca, A., Rocha-Goncalves, F., Rodrigues Gomes, M., and Cerqueira Gomes, M.
37. Neurohumoral response to sublingual captopril and nifedipine in hypertensive emergencies during a cold pressure test. Contribution to the study of interactions between the sympathic system and renin-angiotensin and the plasma atrial natriuretic factor
- Author
-
Jorge Polonia, Pedro-Nunes, J., Vaz Da Silva, M., Esteves, A. P., Cunha, M. E., Brandao, F. A., and Cerqueirr Gomes, M.
38. Probable exacerbation of myasthenia gravis by ofloxacin [4]
- Author
-
Azevedo, E., Ribiero, J. A., Jorge Polonia, and Pontes, C.
39. Through-to-peak ratio of antihypertensive drugs: Methodological problems and clinical applications | RELACAO VALE-PICO DE MEDICAMENTOS ANTI-HIPERTENSORES: QUESTOES METODOLOGICAS E IMPLICACOES CLINICAS
- Author
-
Jorge Polonia
40. ISVH Society September Newsletter
- Author
-
Wc, Roberts, Zanchetti A, Asmar R, Cameron J, Achimastos A, Agabiti-Rosei E, Cockcroft J, Duprez D, Filipovsky J, Izzo J, Nicolaides A, Sa Cunha R, Struijker-Boudier H, Takazawa K, Van Bortel L, Wang H, Benetos A, Calvo C, Jn, Cohn, Cruickshank K, de Leeuw P, de Luca N, Feely N, Franklin S, Kass D, Kingwell B, Kk, Koh, Laurent S, Mitchell G, Palma-Gamiz J, Pannier B, Cg, Park, Jorge Polonia, Rajkumar C, Schiffrin E, Scuteri A, Sirenko Y, Topouchian J, Toto-Moukouo J, Van Meighem W, and Waeber B
- Subjects
ISVH Society News
41. Postsynaptic a-adrenoceptor subtypes in the internal carotid, mesenteric, splenic, renal and femoral vascular beds of the dog
- Author
-
Jorge Polonia, Guerreiro, M., Guimaraes, S., and Garrett, J.
42. Attenuation by indomethacin of the antihypertensive effects of enalapril may be independent of sodium retention | Atenuacao dos efeitos anti-hipertensores do enalapril pela indometacina. Sua independencia da retencao renal de sodio
- Author
-
Jorge Polonia, Gama, G., and Santos, A.
43. Plasma clearance and effects of α-hANP infused in patients with end-stage renal failure
- Author
-
Tonolo, G., Mcmillan, M., Jorge Polonia, Pazzola, A., Montorsi, P., Soro, A., Glorioso, N., and Richards, M. A.
44. New perspectives in the treatment of hypertension: The contribution of rilmenidine | Novas perspectivas no tratamento da hipertensao: A contribuicao da rilmenidina
- Author
-
Jorge Polonia
45. A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence
- Author
-
Manuela Morato, Inês Ribeiro-Vaz, Renato Ferreira da Silva, and Jorge Polonia
- Subjects
Pharmaceutical Preparations ,Clinical Biochemistry ,Humans ,General Medicine ,Pandemics ,Biochemistry ,COVID-19 Drug Treatment - Abstract
Since the breakthrough of the pandemic, several drugs have been used to treat COVID-19 patients. This review aims to gather information on adverse events (AE) related to most drugs used in this context.We performed a literature search to find articles that contained information about AE in COVID-19 patients. We analysed and reviewed the most relevant studies in the Medline (via PubMed), Scopus and Web of Science. The most frequent AE identified were grouped in our qualitative analysis by System Organ Class (SOC), the highest level of the MedDRA medical terminology for each of the drugs studied.The most frequent SOCs among the included drugs are investigations (n = 7 drugs); skin and subcutaneous tissue disorders (n = 5 drugs); and nervous system disorders, infections and infestations, gastrointestinal disorders, hepatobiliary disorders, and metabolism and nutrition disorders (n = 4 drugs). Other SOCs also emerged, such as general disorders and administration site conditions, renal and urinary disorders, vascular disorders and cardiac disorders (n = 3 drugs). Less frequent SOC were eye disorders, respiratory, thoracic and mediastinal disorders, musculoskeletal and connective tissue disorders, and immune system disorders (n = 2 drugs). Psychiatric disorders, and injury, poisoning and procedural complications were also reported (n = 1 drug).Some SOCs seem to be more frequent than others among the COVID-19 drugs included, although neither of the studies included reported causality analysis. For that purpose, further clinical studies with robust methodologies, as randomised controlled trials, should be designed and performed.
- Full Text
- View/download PDF
46. Atrial natriuretic peptides and renin release
- Author
-
Richards, A. M., Tonolo, G., Tree, M., Robertson, J. I. S., Montorsi, P., Leckie, B. J., and Jorge Polonia
47. Clinical efficacy and safety of enlapril in patients with mild to moderate hypertension | EFICACIA E SEGURANCA CLINICA DO ENALAPRIL EM DOENTES COM HIPERTENSAO LIGEIRA A MODERADA
- Author
-
Jorge Polonia, Brandao, F., Rocha-Concalves, F., and Cerqueira Gomes, M.
48. Double-blind comparison of cilazapril and atenolol in mild-to-moderate hypertension
- Author
-
Jorge Polonia, Campelo, M., Camoes, I., Bernardo, F., Vaz Da Silva, M., Nunes, J. P., Esteves, A., and Brandao, F.
49. Postsynaptic alpha-adrenoceptor subtypes in the internal carotid, mesenteric, splenic, renal and femoral vascular beds of the dog
- Author
-
Jorge Polonia, Guerreiro M, Guimarães S, and Garrett J
- Subjects
Male ,Yohimbine ,Blood Pressure ,Prazosin ,Receptors, Adrenergic, alpha ,Muscle, Smooth, Vascular ,Mesenteric Arteries ,Normetanephrine ,Femoral Artery ,Norepinephrine ,Phenylephrine ,Carotid Arteries ,Dogs ,Renal Artery ,Animals ,Female ,Spleen - Abstract
Pressor effects of noradrenaline, phenylephrine and alpha-methylnoradrenaline and the inhibition of these effects by prazosin or yohimbine (or both) were studied in vivo in the renal, splenic, femoral, anterior mesenteric and internal carotid vascular beds of the dog. In all the vascular beds noradrenaline was more potent than alpha-methylnoradrenaline and alpha-methylnoradrenaline was more potent than phenylephrine. However, the ratios between the ED50 for phenylephrine and the ED50 for alpha-methylnoradrenaline in the mesenteric, in the femoral, in the splenic and in the renal circulations was 2.19, 1.89, 1.48, and 1.33, respectively, showing that the relative potency of phenylephrine increased in that order. In the internal carotid vascular bed it was not possible to determine any value. Furthermore, in the renal vascular bed, prazosin (100 micrograms/kg) inhibited pressor responses to all agonists more readily than yohimbine (250 micrograms/kg) and yohimbine was more potent than prazosin against all the agonists in the mesenteric and in the femoral vascular beds. Our results show that: there are both postsynaptic alpha 1- and alpha 2-adrenoceptors in the four vascular beds; the contribution of alpha 2-adrenoceptors to pressor responses to sympathomimetic agents is maximal in the mesenteric followed by the femoral, the splenic and the renal vascular bed, whereas the participation of alpha 1-adrenoceptors is maximal in the renal and progressively smaller in the splenic, in the femoral and in the mesenteric vascular bed, where it reaches the lowest value.
50. Monitoring blood concentation of drugs in clinical practice. A critical view [23] | MONITORIZACAO DAS CONCENTRACOES SNAGUINEAS DE FARMACOS. ANALISE CRITICA DO SEU LUGAR NA PRATICA CLINICA [23]
- Author
-
Jorge Polonia
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.